Search Results
Your search for ,iII matches 9386 pages
Showing 1 - 50Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for...
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Zhou et al, the phase III WU-KONG28 trial has shown that first-line sunvozertinib improved progression-free survival vs chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC)...
Teclistamab in Previously Treated Multiple Myeloma
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Touzeau et al, an interim analysis of the phase III MajesTEC-9 trial has shown improved progression-free survival with teclistamab vs investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd)...
Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss...
Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; ...
Jamie E. Chaft, MD, FASCO, on Nivolumab After Surgery and Adjuvant Chemotherapy in NSCLC
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivolumab after standard-of-care adjuvant therapy in patients with resected lung adenocarcinoma without...
Lorenza Rimassa, MD, and David James Pinato, MD, PhD, on Expanding the HCC Treatment Landscape: TACE Combinations, Immunotherapies, and Bispecific Antibodies
Lorenza Rimassa, MD, of IRCCS Humanitas Research Hospital, and David James Pinato, MD, PhD, of Imperial College London, discuss positive phase III findings in intermediate-stage hepatocellular carcinoma (HCC) with immunotherapy-based combinations with TACE, second-line data from IMbrave251, and...
John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertinib monotherapy vs platinum-based therapy as first-line treatment for patients with advanced...
Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer...
Mazyar Shadman, MD, on CLL/SLL: Sonorotoclax and Zanubrutinib
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma...
Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma
In an analysis reported in The Lancet, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma. Study Details In the international (13 European countries and Israel) open-label trial, 870...
Giannis S. Mountzios, MD, on SCLC: Intracranial Effect of Tarlatamab vs Chemotherapy
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of...
Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene...
Misty Dawn Shields, MD, PhD, on SCLC: Expert Point of View
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s meeting. The first focuses on a post hoc analysis of the phase III DeLLphi-304 trial (Abstract 8006),...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its...
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Results from the global phase III ASCENT-04 clinical trial found that sacituzumab govitecan combined with pembrolizumab improved progression-free survival 2 (PFS2) in patients with PD-L1–positive metastatic triple-negative breast cancer when compared to chemotherapy with pembrolizumab. PFS2 is an...
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
According to findings from a phase III trial presented at the 2026 ASCO Annual Meeting (Abstract LBA6007), a low-cost regimen combining triple oral metronomic chemotherapy with ultra-low-dose immunotherapy significantly improved survival and reduced toxicity compared with platinum-based...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line treatment can reduce tumor progression in patients with aggressive diffuse large B-cell lymphoma...
Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with...
Bjorn Henning Gronberg, MD, PhD, on Extensive-Stage SCLC: Concurrent TRT and Chemoimmunotherapy
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
Jason R. Westin, MD, FASC, on Updated Safety and Efficacy From the SUNMO Trial in LBCL
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or...
Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based...
Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in ...
Julie R. Brahmer, MD, FASCO, on Previously Untreated Advanced Squamous NSCLC: HARMONi-6 Trial
Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert commentary on the overall survival results from the phase III HARMONi-6 trial presented in this year’s...
Shailender Bhatia, MD, on Adjuvant Avelumab in Patients With Metastatic Merkel Cell Carcinoma
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node...
Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View
Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abstract LBA5).
Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases
A phase III randomized trial presented at the 2026 ASCO Annual Meeting found that implanted tile-based radiation therapy significantly reduced local recurrence and improved overall survival compared with postoperative stereotactic radiotherapy (SRT) in patients undergoing surgical resection of...
Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows
Updated results from the phase III SENOMAC trial suggest that many patients with early-stage breast cancer and limited spread to sentinel lymph nodes can safely forgo axillary lymph node dissection (ALND), avoiding substantial long-term arm morbidity without compromising survival. The findings were ...
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC), based on data presented ...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Daraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer
Median Overall survival was nearly doubled among patients with previously treated metastatic pancreatic cancer who received the multiselective RAS(ON) inhibitor daraxonrasib in the phase III RASolute 302 trial, the results of which were presented at the Plenary Session of the 2026 ASCO Annual...
PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer
Adding the androgen receptor pathway inhibitor apalutamide to androgen-deprivation therapy (ADT) before and after radical prostatectomy significantly improves outcomes for patients with localized high-risk prostate cancer, according to findings from the phase III PROTEUS trial presented during the...
Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both...
John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective
Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally...
Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic...
Jonathan W. Goldman, MD, on RET Fusion–Positive NSCLC: Adjuvant Selpercatinib
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small...
Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with...
Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or...
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of...
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
In analyses from the phase III ARANOTE trial reported in The Lancet Oncology, Morgans et al found that darolutamide was associated with prolonged times to worsening pain and worsening health-related quality of life (QOL) compared with placebo in patients with metastatic hormone-sensitive prostate...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins). Results from the phase III...
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Efficacy and Safety Efficacy...
Long-Term EORTC Trial Challenges Assumptions About Lymph Node Radiation Therapy in Breast Cancer
Final results from a landmark European Organisation for Research and Treatment of Cancer (EORTC) randomized trial with more than 20 years of follow-up have shown that irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes reduces breast cancer mortality but does not...
